- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Rhythm Pharmaceuticals Inc (RYTM)
The Rhythm Pharma share price today is 85.70 %REPORT_CURRENCY%, view NASDAQ RYTM stock exchange data. Track the latest Rhythm Pharma share price with real-time updates on RYTM stock performance including market cap, day range, 52-week range and dividend yield. Access RYTM charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
83.12
86.39
52 wk Range
55.31
122.20
Earnings results expected in 9 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
83.1286.39
52 wk Range
55.31122.20
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RYTM Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
137.67
Upside
+60.64%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock price movements are quite volatile
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Rhythm Pharmaceuticals Inc Earnings Call Summary for Q4/2025
- Rhythm Pharmaceuticals beat Q4 2025 expectations with EPS of -$0.73 vs. forecast -$0.82 and revenue of $57.3M vs. expected $55.24M.
- Full-year 2025 revenue reached $194.8M, up 50% from 2024, driven by 10% increase in patients on IMCIVREE therapy globally.
- Stock rose 3.38% to $102.5 in premarket trading; analysts set price targets between $125-$167, suggesting 43% upside potential.
- Q4 revenue split: $39M U.S. (68%) and $18.3M ex-U.S. (32%); company maintains 89.4% gross profit margin despite rising SG&A expenses.
- Management highlighted positive Bivamelagon HO trial results and commitment to pipeline expansion while managing operational cost pressures.
Last Updated: 26-02-2026, 07:46 pm
Read Full TranscriptCompare RYTM to Peers and Sector
Metrics to compare | RYTM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRYTMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −29.0x | 4.9x | −0.4x | |
PEG Ratio | −1.02 | −0.02 | 0.00 | |
Price/Book | 42.1x | 5.0x | 2.6x | |
Price / LTM Sales | 30.8x | 14.3x | 3.2x | |
Upside (Analyst Target) | 63.4% | 82.5% | 46.2% | |
Fair Value Upside | Unlock | 4.3% | 7.2% | Unlock |
Analyst Ratings
15 Buy
1 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 137.67
(+60.64% Upside)
Earnings
Latest Release
26-02-2026
EPS / Forecast
-0.73 / -0.82
Revenue / Forecast
57.3M / 55.24M
FAQ
What Is the Rhythm Pharma (RYTM) Share Price Today?
The Rhythm Pharma share price today is 85.70 USD.
What is the current Rhythm Pharma (RYTM) share price and day range?
As of 26-04-2026, the Rhythm Pharma share price is 85.70 USD, with a previous close of 85.21 USD. The share price has ranged from 83.12 to 86.39 USD today, while the 52-week range spans from 55.31 to 122.20 USD.
What Is the Rhythm Pharma Market Cap?
As of today, Rhythm Pharma market cap is 5.85B.
What Is the Rhythm Pharma (RYTM) Share Price Target?
The average 12-month share price target for Rhythm Pharma is 137.67 USD, with a high estimate of 158 USD and a low estimate of 105 USD. 15 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +60.64% Upside potential.
What Is Rhythm Pharma's Earnings Per Share (TTM)?
The Rhythm Pharma EPS (TTM) is -3.11.
When Is the Next Rhythm Pharma Earnings Date?
Rhythm Pharma will release its next earnings report on 05-05-2026.
From a Technical Analysis Perspective, Is RYTM a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Rhythm Pharma Trade On?
Rhythm Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Rhythm Pharma?
The stock symbol for Rhythm Pharma is "RYTM."
How Many Times Has Rhythm Pharma Stock Split?
Rhythm Pharma has split 0 times.
How Many Employees Does Rhythm Pharma Have?
Rhythm Pharma has 414 employees.
What Is the RYTM Premarket Price?
RYTM's last pre-market stock price is 85.90 USD. The pre-market share volume is 110.00, and the stock has changed by 0.69 USD, or 0.81%.
What Is the RYTM After Hours Price?
RYTM's last after hours stock price is 85.01 USD, the stock has changed by -0.69 USD, or -0.81%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.